Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.

Caregivers Palliative care Perioperative care Peritoneal neoplasms Psychooncology Quality of life

Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
07 Jun 2024
Historique:
received: 30 03 2024
revised: 27 05 2024
accepted: 02 06 2024
medline: 9 6 2024
pubmed: 9 6 2024
entrez: 8 6 2024
Statut: aheadofprint

Résumé

Patients with advanced gynecologic (GYN) and gastrointestinal (GI) cancers frequently develop peritoneal carcinomatosis (PC), which limits prognosis and diminishes health-related quality of life (HRQoL). Palliative procedures may improve PC symptoms, yet patients and caregivers report feeling unprepared to manage ostomies, catheters, and other complex needs. Our objectives were to (1) assess the feasibility of an efficacy trial of a nurse-led telehealth intervention (BOLSTER) for patients with PC and their caregivers; and (2) assess BOLSTER's acceptability, potential to improve patients' HRQoL and self-efficacy, and potential impact on advance care planning (ACP). Pilot feasibility RCT. Recently hospitalized adults with advanced GYN and GI cancers, PC, and a new complex care need and their caregivers were randomized 1:1 to BOLSTER or enhanced discharge planning (EDP). We defined feasibility as a ≥ 50% approach-to-consent ratio and acceptability as ≥70% satisfaction with BOLSTER. We assessed patients' HRQoL and self-efficacy at baseline and six weeks, then compared the proportion experiencing meaningful improvements by arm. ACP documentation was identified using natural language processing. We consented 77% of approached patients. In the BOLSTER arm, 91.0% of patients and 100.0% of caregivers were satisfied. Compared to EDP, more patients receiving BOLSTER experienced improvements in HRQoL (68.4% vs. 40.0%) and self-efficacy for managing symptoms (78.9% vs. 35.0%) and treatment (52.9% vs. 42.9%). The BOLSTER arm had more ACP documentation. BOLSTER is a feasible and acceptable intervention with the potential to improve patients' HRQoL and promote ACP. An efficacy trial comparing BOLSTER to usual care is underway. ClinicalTrials.gov: NCT03367247; PI: Wright.

Identifiants

pubmed: 38851039
pii: S0090-8258(24)00275-0
doi: 10.1016/j.ygyno.2024.06.001
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03367247']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Rachel A Pozzar (RA)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: rachel_pozzar@dfci.harvard.edu.

Andrea C Enzinger (AC)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Catherine Howard (C)

Dana Farber Cancer Institute, Boston, MA, United States.

Anna Tavormina (A)

Dana Farber Cancer Institute, Boston, MA, United States.

Ursula A Matulonis (UA)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Susana Campos (S)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Joyce F Liu (JF)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Neil Horowitz (N)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Panagiotis A Konstantinopoulos (PA)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Carolyn Krasner (C)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Jaclyn A Wall (JA)

University of Alabama, Birmingham, AL, United States.

Kate Sciacca (K)

Dana Farber Cancer Institute, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States.

Larissa A Meyer (LA)

University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Charlotta Lindvall (C)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States.

Alexi A Wright (AA)

Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Classifications MeSH